New Alzheimer’s drug clouds outlook for Medicare premiums next year
The decision by U.S. drug regulators last month to approve a controversial treatment for Alzheimer’s disease could fuel an unusually large increase in Medicare premiums next year, but the outlook is clouded by a number of factors that will play out later this year.
Biogen Inc’s (BIIB.O) drug Aduhelm could create hope for millions of older Americans afflicted with Alzheimer’s – if it is effective in combating the disease. But the U.S. Food and Drug Administration (FDA) approved the drug despite objections from its own scientific advisory panel, which voted nearly unanimously that clinical trials did not demonstrate its effectiveness. read more
Medicare typically covers FDA-approved drugs – but this one comes with an eye-popping price tag set by its maker – $56,000 per patient annually. That figure does not include other associated care that could add tens of thousands of dollars of additional costs.
Retiree News 
Comments are closed.